Is ZIOP or RYLD a better dividend investment in 2026?

ZIOP currently yields 231.03% with a 5% 5-year dividend growth rate. RYLD yields 12.14% with 5% growth. The better choice depends on your goal: ZIOP offers higher current income.

What is the dividend yield difference between ZIOP and RYLD?

ZIOP has a forward dividend yield of 231.03% ($2.00/share annually). RYLD yields 12.14% ($1.81/share annually). The yield gap is 218.89 percentage points.

Home › Compare › ZIOP vs RYLD

ZIOP vs RYLD: Dividend Comparison 2026

ZIOP yields 231.03% · RYLD yields 12.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ZIOP wins by $281.95M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ZIOP

● Live price

231.03%

Share price

$0.87

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$281.99M

Annual income

$152,307,756.02

Full ZIOP calculator →

RYLD

● Live price

12.14%

Share price

$14.95

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.5K

Annual income

$2,587.35

Full RYLD calculator →

Portfolio growth — ZIOP vs RYLD

📍 ZIOP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ZIOP	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ZIOP + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ZIOP pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZIOP

Annual income on $10K today (after 15% tax)

$19,637.29/yr

After 10yr DRIP, annual income (after tax)

$129,461,592.62/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,031.60/yr

After 10yr DRIP, annual income (after tax)

$2,199.25/yr

At 15% tax rate, ZIOP beats the other by $129,459,393.37/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZIOP + RYLD for your $10,000?

ZIOP: 50%RYLD: 50%

100% RYLD50/50100% ZIOP

Portfolio after 10yr

$141.02M

Annual income

$76,155,171.68/yr

Blended yield

54.00%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZIOP buys

RYLD buys

No recent congressional trades found for ZIOP or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricZIOPRYLD

Forward yield	231.03% ✓	12.14%
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$281.99M ✓	$44.5K
Annual income after 10y	$152,307,756.02 ✓	$2,587.35
Total dividends collected	$267.75M ✓	$18.8K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: ZIOP vs RYLD ($10,000, DRIP)

Year	ZIOP Portfolio	ZIOP Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$33,803	$23,102.69	$11,914	$1,213.65	+$21.9K → ZIOP
2	$109,153	$72,984.41	$14,099	$1,351.30	+$95.1K → ZIOP
3	$337,052	$220,258.08	$16,580	$1,494.55	+$320.5K → ZIOP
4	$996,281	$635,635.69	$19,384	$1,642.61	+$976.9K → ZIOP
5	$2,821,960	$1,755,939.31	$22,535	$1,794.70	+$2.80M → ZIOP
6	$7,667,803	$4,648,304.92	$26,063	$1,950.00	+$7.64M → ZIOP
7	$20,008,593	$11,804,044.41	$29,995	$2,107.69	+$19.98M → ZIOP
8	$50,195,948	$28,786,753.46	$34,361	$2,266.99	+$50.16M → ZIOP
9	$121,203,020	$67,493,355.30	$39,194	$2,427.12	+$121.16M → ZIOP
10	$281,994,987	$152,307,756.02	$44,525	$2,587.35	+$281.95M → ZIOP

ZIOP vs RYLD: Complete Analysis 2026

ZIOP — Stock

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

Full ZIOP Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this ZIOP vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZIOP vs SCHD ZIOP vs JEPI ZIOP vs O ZIOP vs KO ZIOP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.